Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Z&Z
Houston, Texas, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
ZZ Biotech is developing 3K3A-APC, a genetically engineered variant of activated Protein C. It received FDA Fast Track designation for acute ischemic stroke. Phase 2 trials (RHAPSODY) established maximally tolerated dose; additional Phase 2 trials ongoing for stroke via NIH StrokeNet and ALS. Drug advanced for wound therapies by Dermatherix.[2][7][9]
- Therapeutic areas
- EndocrinologyCardiovascularNeurologyDermatology
- Modalities
- Recombinant protein
- Industry
- Biotech
02
Partnerships
National Institute of Neurological Disorders and Stroke (NINDS/NIH)Cedars-SinaiBroadview VenturesDermatherix
Beyond the preview
Go deeper on Z&Z.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Z&Z.